Companies /Consumer Defensive

Clorox Company

NYSE: CLX Household & Personal Products
$84.89
▼ $2.27 (−2.60%) today
Markets closed · 5:37pm ET

Q3 2026 Earnings

Reported Apr 30, 2026, 4:12pm ET · SEC source
$1.64
Beat +9.33%
EPS · est. $1.50
$1.7B
Beat +0.10%
Revenue · est. $1.7B
−3.0%
Trailing market
CLX vs S&P since report
2 quarters
Consecutive EPS beats

Market Reaction

% change · around the report
−8%−4%0Apr 30May 1report 4:12pm ETearnings+0.1%−7.2%
−8%−4%0Apr 30May 1earnings+0.1%−7.2%
CLX −7.2%S&P 500 +0.1%
−8%−4%0Apr 30May 1report 4:12pm ETearnings+0.9%−7.2%
−8%−4%0Apr 30May 1earnings+0.9%−7.2%
CLX −7.2%NASDAQ +0.9%
−4%0+4%Apr 29May 8report 4:12pm ETearnings+2.5%+1.9%
−4%0+4%Apr 29May 8earnings+2.5%+1.9%
CLX +1.9%S&P 500 +2.5%
−4%0+4%Apr 29May 8report 4:12pm ETearnings+6.5%+1.9%
−4%0+4%Apr 29May 8earnings+6.5%+1.9%
CLX +1.9%NASDAQ +6.5%
−9.67%
Day of report
−0.72%
Next session
+5.80%
One week
+1.63%
30 days

S&P 500 over the same 30 days: +4.66%.

Did CLX Beat Earnings? Q3 2026 Results

Clorox posted a headline beat in its fiscal third quarter, but the real story was the sharp downgrade to its full-year outlook that overshadowed stronger-than-expected earnings. The company reported adjusted EPS of $1.64, clearing the $1.55 consensus estimate by 6.05%, while revenue of $1.67 billion edged past expectations by 0.10% and held essentially flat year-over-year, up just 0.1%. The adjusted earnings gain, up 13% from $1.45 a year ago, was driven primarily by cost savings and lower selling and administrative expenses, though gross margin contracted 140 basis points to 43.2% as higher manufacturing and logistics costs took a toll. The more consequential news was the company's substantially lowered FY2026 guidance, with full-year adjusted EPS now expected at $5.45 to $5.65, down from a prior range of $5.95 to $6.30, as the ERP transition inventory normalization, GOJO acquisition costs, and higher energy costs weigh on the back half; organic sales are now seen declining approximately 9% for the full year.

Key Takeaways
  • Cost savings contributed 170 basis points to gross margin
  • Lower advertising investments and lower selling and administrative expenses drove adjusted EPS growth
  • Higher manufacturing and logistics costs (210 bps headwind) and unfavorable mix pressured gross margin
  • Household segment volume growth of 3 points driven by shipment ahead of consumption in Cat Litter and Grilling
  • International segment benefited from favorable foreign exchange rates (6 points) and higher volume
  • Lifestyle segment declined on lower consumption and retail inventory adjustments
  • Glad joint venture termination payment of $476 million reduced year-to-date operating cash flow

“Our third-quarter results were mixed, with continued momentum in some parts of our portfolio and slower-than-anticipated market share recovery in others.”

Clorox CEO, on the earnings call

Forward Guidance & Outlook

Clorox significantly lowered its FY2026 outlook. Net sales are now expected to decline about 6% (previously low end of 6%–10% decline), including ~3 points of positive impact from the GOJO acquisition, less than 1 point of negative impact from the VMS divestiture, and less than 1 point of positive FX impact. Organic sales are now expected to decline about 9% (previously low end of 5%–9% decline), including ~7.5 points of headwind from ERP transition inventory normalization. Gross margin is now expected to decline 250–300 basis points (previously 50–100 bps decline), reflecting GOJO transaction costs (~60 bps headwind), ERP shipment reversal (~100 bps), and higher energy costs. Full-year GAAP diluted EPS is expected at $4.78–$4.98 (previously low end of $5.60–$5.95), a 24%–27% YoY decrease. Full-year adjusted EPS is expected at $5.45–$5.65 (previously low end of $5.95–$6.30), a 27%–29% YoY decrease, including 2–4 cents dilution from GOJO. The ~$0.90 ERP transition shipment reversal remains the most significant driver of the year-over-year decline. SG&A is still expected at ~16% of net sales, advertising at ~11% of net sales, and effective tax rate at ~24%.

CLX YoY Financials

Q3 2026 vs Q3 2025 · SEC filings Q3 2025 Q3 2026
$0$500.0M$1.0B$1.5B$1.7B$1.7BRevenue$739.0M$722.0MGross Profit$186.0M$187.0MNet Income
$0$500.0M$1.0B$1.5BRevenueGross ProfitNet Income

CLX Revenue by Segment

Health and Wellness$629.0M+0.0%
Household$482.0M+3.0%
Lifestyle$277.0M−9.0%
International$285.0M+8.0%

Figures from SEC filings and company reports. Not investment advice.